Albany, NY, United States of America

Andrew B Yu

This inventor holds 1 USPTO granted patent. Top assignee: Sterling Drug Inc.. Active years: 1983.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 1983

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andrew B Yu - Innovator in Pharmaceutical Technology

Introduction

Andrew B Yu is a notable inventor based in Albany, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained-release formulations. His innovative approach has led to advancements that benefit both patients and the pharmaceutical industry.

Latest Patents

Andrew B Yu holds a patent for a sustained-release pharmaceutical tablet and the process for its preparation. This invention consists of drug pellets encapsulated with a water-soluble film-forming substance and a water-insoluble film-forming substance. These components are blended and compressed into tablet form using a compressible tableting mixture. This patent represents a significant step forward in the delivery of medications, ensuring that drugs are released in a controlled manner over time.

Career Highlights

Andrew is currently employed at Sterling Drug Inc., where he continues to work on innovative pharmaceutical solutions. His expertise in drug formulation and delivery systems has positioned him as a valuable asset in the industry.

Collaborations

Andrew collaborates with Phillip M John, who is also involved in the pharmaceutical sector. Their combined efforts contribute to the advancement of drug delivery technologies.

Conclusion

Andrew B Yu's work in the field of sustained-release pharmaceuticals exemplifies the impact of innovation on healthcare. His contributions are paving the way for more effective medication delivery systems, ultimately improving patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…